PNC Financial Services Group
BDTX icon

PNC Financial Services Group’s Black Diamond Therapeutics BDTX Stock Holding History

PNC Financial Services Group’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,000
Closed -$2.14K – 4904
2024
Q4 		$2.14K Hold
1,000
– – ﹤0.01% 4266
2024
Q3 		$4.35K Hold
1,000
– – ﹤0.01% 4079
2024
Q2 		$4.66K Hold
1,000
– – ﹤0.01% 4012
2024
Q1 		$5.07K Hold
1,000
– – ﹤0.01% 3952
2023
Q4 		$2.81K Hold
1,000
– – ﹤0.01% 4105
2023
Q3 		$2.87K Buy
+1,000
New +$3.68K ﹤0.01% 4137
2021
Q1 		– Sell
-3,920
Closed -$126K – 4107
2020
Q4 		$126K Buy
+3,920
New +$129K ﹤0.01% 2357

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

PNC Financial Services Group's BDTX Position: Q1 2025 in Review

PNC Financial Services Group sold out of Black Diamond Therapeutics (BDTX) in Q1 2025, closing a stake of 1,000 shares — an estimated $2.14K sold.

PNC Financial Services Group first reported a position in BDTX in Q4 2020 and held it in 7 quarters. The position peaked at $126K in Q4 2020. 84 funds tracked by Wall St. Rank hold BDTX as of Q1 2025.

  • PNC Financial Services Group reported no remaining Black Diamond Therapeutics position as of Q1 2025 after selling out during the quarter.
  • PNC Financial Services Group sold 1,000 Black Diamond Therapeutics shares in Q1 2025, an estimated $2.14K.
  • PNC Financial Services Group first reported a position in Black Diamond Therapeutics in Q4 2020 and held it in 7 quarters.
  • PNC Financial Services Group's Black Diamond Therapeutics position peaked at $126K in Q4 2020.
  • 84 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2025.

Based on PNC Financial Services Group's 13F filing for Q1 2025, filed 9 May 2025.